A detailed history of Joel Isaacson & Co., LLC transactions in Dexcom Inc stock. As of the latest transaction made, Joel Isaacson & Co., LLC holds 8,660 shares of DXCM stock, worth $630,707. This represents 0.03% of its overall portfolio holdings.

Number of Shares
8,660
Previous 8,660 -0.0%
Holding current value
$630,707
Previous $981,000 40.88%
% of portfolio
0.03%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 26, 2023

SELL
$112.47 - $130.98 $25,305 - $29,470
-225 Reduced 2.53%
8,660 $1.11 Million
Q4 2022

Jan 27, 2023

BUY
$84.98 - $122.67 $177,183 - $255,766
2,085 Added 30.66%
8,885 $0
Q2 2022

Jul 15, 2022

BUY
$67.99 - $132.89 $346,749 - $677,738
5,100 Added 300.0%
6,800 $507,000
Q1 2022

Apr 21, 2022

SELL
$94.08 - $130.2 $564 - $781
-6 Reduced 0.35%
1,700 $817,000
Q4 2021

Jan 19, 2022

BUY
$129.87 - $162.82 $779 - $976
6 Added 0.35%
1,706 $916,000
Q2 2021

Jul 20, 2021

SELL
$80.99 - $107.93 $68,841 - $91,740
-850 Reduced 33.33%
1,700 $726,000
Q4 2020

Jan 22, 2021

SELL
$78.0 - $104.5 $39,000 - $52,250
-500 Reduced 16.39%
2,550 $943,000
Q2 2020

Jul 21, 2020

SELL
$62.68 - $105.34 $247,586 - $416,093
-3,950 Reduced 56.43%
3,050 $1.24 Million
Q4 2019

Jan 24, 2020

SELL
$36.62 - $57.29 $29,295 - $45,832
-800 Reduced 10.26%
7,000 $1.53 Million
Q3 2019

Oct 15, 2019

BUY
$35.53 - $43.8 $46,189 - $56,939
1,300 Added 20.0%
7,800 $1.16 Million
Q2 2019

Jul 11, 2019

SELL
$27.84 - $38.92 $55 - $77
-2 Reduced 0.03%
6,500 $974,000
Q4 2018

Jan 18, 2019

BUY
$26.99 - $37.37 $53 - $74
2 Added 0.03%
6,502 $917,000
Q1 2018

May 01, 2018

BUY
$13.06 - $18.54 $26,120 - $37,080
2,000 Added 44.44%
6,500 $482,000
Q3 2017

Nov 02, 2017

BUY
$11.36 - $18.98 $51,120 - $85,410
4,500
4,500 $220,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $28.1B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Joel Isaacson & Co., LLC Portfolio

Follow Joel Isaacson & Co., LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Joel Isaacson & Co., LLC, based on Form 13F filings with the SEC.

News

Stay updated on Joel Isaacson & Co., LLC with notifications on news.